瑞科生物新疫苗III期临床研究已完成全部受试者入组
财中社1月2日电瑞科生物-B（02179）发布自愿公告，宣布其自主研发的新佐剂重组带状疱疹疫苗REC610的III期临床研究已顺利完成全部受试者的入组。该研究在云南、河南和山西共计18个研究中心招募了24640名40岁及以上的健康受试者，旨在评估疫苗的保护效力、安全性及免疫原性。
带状疱疹在中国每年约有600万人罹患，且近年来发病有逐步年轻化的趋势。REC610疫苗采用新型佐剂BFA01，能够诱导机体产生高水平的VZV糖蛋白E(gE)特异性CD4+T细胞和抗体，拟用于40岁及以上成人预防带状疱疹。目前，中国市场上带状疱疹仅有葛兰素史克的Shingrix®上市销售，国产替代需求强烈。股东和潜在投资者需谨慎行事，因本集团未必能成功开发或营销REC610。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10